NRP2 and triple-negative breast carcinoma: Anti-Nrp2 antibody treatment inhibited the growth of human triple negative breast cancer cells in immunocompromised mice, impeding an autocrine feedback loop of Nrp2/α6β1/GLI1/BMI-1 [39].